How to Buy concordbio Shares on Fincept?
You can buy Concord Biotech Limited shares on Different Brokers & Banks by creating an account and completing KYC verification online.
NSE: Concord Biotech Limited Share Price Today, Share Analysis, Latest Updates & Insights | Fincept
Stay informed with the latest announcements for Concordbio, including updates on board meetings and corporate actions.
Concord Biotech Limited - https://www.concordbiotech.com
Concord Biotech Limited, a biopharma company, engages in the research and development, manufacturing, marketing, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, and pimecrolimus for immunosuppressants therapeutic segment; temsirolimus, everolimus, romidepsin, mitomycin, midostaurin, dactinomycin, staurosporin, mitoguazone, and everolimus premix for oncology therapeutic segment; mupirocin, mupirocin calcium, polymyxin B sulfate, fidaxomicin, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, micafungin sodium, amphotericin B, and nystatin for anti-fungal therapeutic segment; and lovastatin, pravastatin sodium, and enzymes for other applications. In addition, it provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India.
Concord Biotech Limited Share Price Today
2,052.25
OPEN
2,098.05
HIGH
2,038.50
LOW
2,066.55
CLOSE
166 K
VOLUME
21,943 Cr
Market Cap
104241
Average Volume
Healthcare
Sector
NSI
Exchange
Concord Biotech Limited Share Analysis & 2025 Insights
Investor Presentations
| Date | Description | Download |
|---|
SIP
Lumpsum
Invested Amount: ₹
Estimated Returns: ₹
Total Value: ₹
NSE: CONCORDBIO Stock Actions
Company |
Symbol |
ISIN |
Subject |
Ex Date |
Face Value |
Broadcast Date |
|---|---|---|---|---|---|---|
Concord Biotech Limited |
CONCORDBIO |
INE338H01029 |
Annual General Meeting |
21 Jun 2024 |
1 |
N/A |
Concord Biotech Limited |
CONCORDBIO |
INE338H01029 |
Dividend - Rs 8.75 Per Share |
21 Jun 2024 |
1 |
N/A |
NSE: CONCORDBIO Recent Announcements
Symbol |
Date |
Description |
Industry |
|---|---|---|---|
CONCORDBIO |
24 Dec 2024, 13:20:02 |
Trading Window-XBRL |
N/A |
CONCORDBIO |
24 Dec 2024, 13:18:52 |
Trading Window |
N/A |
CONCORDBIO |
13 Dec 2024, 10:08:48 |
Acquisition-XBRL |
N/A |
CONCORDBIO |
12 Dec 2024, 11:50:23 |
Others |
N/A |
CONCORDBIO |
19 Nov 2024, 11:25:47 |
Analysts/Institutional Investor Meet/Con. Call Updates |
N/A |
NSE: CONCORDBIO Corporate Governance
Name |
Symbol |
Timestamp |
Submission Date |
XBRL Document |
|---|---|---|---|---|
Concord Biotech Limited |
CONCORDBIO |
10 Oct 2024, 10:25:00 |
10 Oct 2024, 10:25:00 |
|
Concord Biotech Limited |
CONCORDBIO |
18 Jul 2024, 14:23:00 |
18 Jul 2024, 14:23:00 |
|
Concord Biotech Limited |
CONCORDBIO |
15 Apr 2024, 13:05:00 |
15 Apr 2024, 13:30:00 |
|
Concord Biotech Limited |
CONCORDBIO |
12 Jan 2024, 15:45:00 |
12 Jan 2024, 16:15:00 |
|
Concord Biotech Limited |
CONCORDBIO |
16 Oct 2023, 12:46:00 |
16 Oct 2023, 13:15:00 |
NSE: CONCORDBIO Detailed Governance
Category |
Date of Birth |
Date of Initial Appointment |
DIN |
Director Name |
Status |
|---|---|---|---|---|---|
Chairperson & Executive Director-MD |
03 Sep 1952 |
10 May 2000 |
00055967 |
SUDHIR JAIRAM VAID |
Active |
Executive Director-CEO-MD |
14 Apr 1982 |
04 Dec 2009 |
01857225 |
ANKUR VAID |
Active |
Non-Executive Director |
25 Jul 1963 |
15 Dec 2003 |
00003847 |
RAVI KAPOOR |
Active |
Non-Executive Director |
28 Mar 1971 |
30 Jun 2008 |
00379990 |
RAJIV AMBRISH AGARWAL |
Active |
Independent Director |
09 Jun 1968 |
31 Jan 2017 |
05147844 |
BHARTI KHANNA |
Active |
NSE: CONCORDBIO Board Meetings
Purpose |
Symbol |
Industry |
ISIN |
Name |
Time |
|---|---|---|---|---|---|
Board Meeting Intimation |
CONCORDBIO |
N/A |
INE338H01029 |
Concord Biotech Limited |
06 Nov 2024, 13:57:32 |
Financial Results |
CONCORDBIO |
N/A |
INE338H01029 |
Concord Biotech Limited |
31 Jul 2024, 13:43:03 |
Financial Results/Dividend/Other business matters |
CONCORDBIO |
N/A |
INE338H01029 |
Concord Biotech Limited |
15 May 2024, 13:17:05 |
CONCORD BIOTECH LIMITED has informed the Exchange about Board Meeting to be held on 08-Feb-2024 to consider and approve the Quarterly Unaudited Financial results of the Company for the period ended December 2023 and Other business. |
CONCORDBIO |
N/A |
INE338H01029 |
Concord Biotech Limited |
30 Jan 2024, 11:33:03 |
CONCORD BIOTECH LIMITED has informed the Exchange about Board Meeting to be held on 08-Nov-2023 to consider and approve the Half Yearly Unaudited Financial results of the Company for the period ended September 2023 and Other business. |
CONCORDBIO |
N/A |
INE338H01029 |
Concord Biotech Limited |
25 Oct 2023, 18:04:03 |
NSE: CONCORDBIO Event Calendar
Purpose |
Symbol |
Industry |
ISIN |
Name |
Time |
Description |
|---|---|---|---|---|---|---|
Financial Results |
CONCORDBIO |
- |
INE338H01029 |
Concord Biotech Limited |
06 Nov 2024, 00:00:00 |
To consider and approve the financial results for the period ended September 30, 2024 |
Financial Results |
CONCORDBIO |
- |
INE338H01029 |
Concord Biotech Limited |
31 Jul 2024, 00:00:00 |
To consider and approve the financial results for the period ended Jun 30, 2024 |
Financial Results/Dividend/Other business matters |
CONCORDBIO |
- |
INE338H01029 |
Concord Biotech Limited |
15 May 2024, 00:00:00 |
To consider and approve the financial results for the period ended March 31, 2024, dividend and other business matters |
Financial Results |
CONCORDBIO |
- |
INE338H01029 |
Concord Biotech Limited |
30 Jan 2024, 00:00:00 |
To consider and approve the financial results for the period ended December 31, 2023 |
Financial Results |
CONCORDBIO |
- |
INE338H01029 |
Concord Biotech Limited |
25 Oct 2023, 00:00:00 |
To consider and approve the financial results for the period ended September 30, 2023 |
NSE: CONCORDBIO Balance Sheet Data In (Cr)
| date | period_type | Treasury Shares Number | Ordinary Shares Number | Share Issued | Net Debt | Total Debt | Tangible Book Value | Invested Capital | Working Capital | Net Tangible Assets | Capital Lease Obligations | Common Stock Equity | Total Capitalization | Total Equity Gross Minority Interest | Stockholders Equity | Other Equity Interest | Retained Earnings | Additional Paid In Capital | Capital Stock | Common Stock | Total Liabilities Net Minority Interest | Total Non Current Liabilities Net Minority Interest | Non Current Pension And Other Postretirement Benefit Plans | Non Current Deferred Taxes Liabilities | Long Term Debt And Capital Lease Obligation | Long Term Capital Lease Obligation | Long Term Debt | Long Term Provisions | Current Liabilities | Other Current Liabilities | Current Debt And Capital Lease Obligation | Current Capital Lease Obligation | Current Debt | Pensionand Other Post Retirement Benefit Plans Current | Current Provisions | Payables | Other Payable | Total Tax Payable | Accounts Payable | Total Assets | Total Non Current Assets | Other Non Current Assets | Non Current Prepaid Assets | Investmentin Financial Assets | Available For Sale Securities | Financial Assets Designatedas Fair Value Through Profitor Loss | Long Term Equity Investment | Investmentsin Joint Venturesat Cost | Goodwill And Other Intangible Assets | Other Intangible Assets | Net PPE | Accumulated Depreciation | Gross PPE | Construction In Progress | Other Properties | Machinery Furniture Equipment | Buildings And Improvements | Land And Improvements | Properties | Current Assets | Other Current Assets | Hedging Assets Current | Restricted Cash | Prepaid Assets | Inventory | Finished Goods | Work In Process | Raw Materials | Other Receivables | Taxes Receivable | Accounts Receivable | Allowance For Doubtful Accounts Receivable | Gross Accounts Receivable | Cash Cash Equivalents And Short Term Investments | Other Short Term Investments | Cash And Cash Equivalents | Cash Equivalents | Cash Financial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30T00:00:00 | quarterly | 0.00 | 104,616,204.00 | 104,616,204.00 | 0.00 | 34,236,000.00 | 15,895,956,000.00 | 15,903,792,000.00 | 7,929,398,000.00 | 15,895,956,000.00 | 34,236,000.00 | 15,903,792,000.00 | 15,903,792,000.00 | 15,903,792,000.00 | 15,903,792,000.00 | 15,799,176,000.00 | 0.00 | 0.00 | 104,616,000.00 | 104,616,000.00 | 1,739,656,000.00 | 322,530,000.00 | 0.00 | 291,130,000.00 | 16,067,000.00 | 16,067,000.00 | 0.00 | 15,333,000.00 | 1,417,126,000.00 | 93,516,000.00 | 18,169,000.00 | 18,169,000.00 | 0.00 | 0.00 | 38,594,000.00 | 840,872,000.00 | 0.00 | 19,157,000.00 | 821,715,000.00 | 17,643,448,000.00 | 8,296,924,000.00 | 102,726,000.00 | 0.00 | 90,951,000.00 | 90,951,000.00 | 0.00 | 4,545,000.00 | 0.00 | 7,836,000.00 | 0.00 | 8,060,326,000.00 | 0.00 | 8,060,326,000.00 | 2,486,711,000.00 | 5,573,615,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 9,346,524,000.00 | 214,886,000.00 | 0.00 | 0.00 | 0.00 | 2,504,245,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3,444,457,000.00 | 0.00 | 0.00 | 3,182,936,000.00 | 3,108,936,000.00 | 74,000,000.00 | 0.00 | 0.00 |
| 2024-03-31T00:00:00 | quarterly | 0.00 | 104,616,204.00 | 104,616,204.00 | 0.00 | 97,376,000.00 | 15,263,258,000.00 | 15,328,753,000.00 | 7,540,757,000.00 | 15,263,258,000.00 | 35,078,000.00 | 15,266,455,000.00 | 15,266,455,000.00 | 15,266,455,000.00 | 15,266,455,000.00 | 15,161,839,000.00 | 14,049,950,000.00 | 819,710,000.00 | 104,616,000.00 | 104,616,000.00 | 1,740,630,000.00 | 319,076,000.00 | 19,561,000.00 | 280,645,000.00 | 18,870,000.00 | 18,870,000.00 | 0.00 | 19,561,000.00 | 1,421,554,000.00 | 62,675,000.00 | 78,506,000.00 | 16,208,000.00 | 62,298,000.00 | 0.00 | 39,019,000.00 | 1,266,413,000.00 | 267,122,000.00 | 54,938,000.00 | 944,353,000.00 | 17,007,085,000.00 | 8,044,774,000.00 | 79,799,000.00 | 111,306,000.00 | 0.00 | 49,695,000.00 | 0.00 | 20,586,000.00 | 20,586,000.00 | 3,197,000.00 | 3,197,000.00 | 7,864,785,000.00 | -2,384,583,000.00 | 10,249,368,000.00 | 2,114,824,000.00 | 519,945,000.00 | 4,459,176,000.00 | 2,608,312,000.00 | 547,111,000.00 | 0.00 | 8,962,311,000.00 | 284,933,000.00 | 1,212,000.00 | 56,753,000.00 | 284,552,000.00 | 2,079,538,000.00 | 165,978,000.00 | 1,234,802,000.00 | 678,758,000.00 | 188,839,000.00 | 0.00 | 3,496,089,000.00 | -13,907,000.00 | 3,509,996,000.00 | 2,855,328,000.00 | 2,703,907,000.00 | 151,421,000.00 | 0.00 | 151,421,000.00 |
| 2024-03-31T00:00:00 | annual | 0.00 | 104,616,204.00 | 104,616,204.00 | 0.00 | 97,376,000.00 | 15,263,258,000.00 | 15,328,753,000.00 | 7,540,757,000.00 | 15,263,258,000.00 | 35,078,000.00 | 15,266,455,000.00 | 15,266,455,000.00 | 15,266,455,000.00 | 15,266,455,000.00 | 15,161,839,000.00 | 14,049,950,000.00 | 819,710,000.00 | 104,616,000.00 | 104,616,000.00 | 1,740,630,000.00 | 319,076,000.00 | 19,561,000.00 | 280,645,000.00 | 18,870,000.00 | 18,870,000.00 | 0.00 | 19,561,000.00 | 1,421,554,000.00 | 62,675,000.00 | 78,506,000.00 | 16,208,000.00 | 62,298,000.00 | 0.00 | 39,019,000.00 | 1,266,413,000.00 | 267,122,000.00 | 54,938,000.00 | 944,353,000.00 | 17,007,085,000.00 | 8,044,774,000.00 | 79,799,000.00 | 111,306,000.00 | 0.00 | 49,695,000.00 | 0.00 | 20,586,000.00 | 20,586,000.00 | 3,197,000.00 | 3,197,000.00 | 7,864,785,000.00 | -2,384,583,000.00 | 10,249,368,000.00 | 2,114,824,000.00 | 519,945,000.00 | 4,459,176,000.00 | 2,608,312,000.00 | 547,111,000.00 | 0.00 | 8,962,311,000.00 | 284,933,000.00 | 1,212,000.00 | 56,753,000.00 | 284,552,000.00 | 2,079,538,000.00 | 165,978,000.00 | 1,234,802,000.00 | 678,758,000.00 | 188,839,000.00 | 0.00 | 3,496,089,000.00 | -13,907,000.00 | 3,509,996,000.00 | 2,855,328,000.00 | 2,703,907,000.00 | 151,421,000.00 | 0.00 | 151,421,000.00 |
| 2023-09-30T00:00:00 | quarterly | 0.00 | 104,616,204.00 | 104,616,204.00 | 126,518,000.00 | 229,667,000.00 | 13,537,683,000.00 | 13,730,385,000.00 | 5,882,004,000.00 | 13,537,683,000.00 | 42,369,000.00 | 13,543,087,000.00 | 13,543,087,000.00 | 13,543,087,000.00 | 13,543,087,000.00 | 13,438,471,000.00 | 0.00 | 0.00 | 104,616,000.00 | 104,616,000.00 | 1,967,168,000.00 | 292,699,000.00 | 0.00 | 246,930,000.00 | 26,715,000.00 | 26,715,000.00 | 0.00 | 19,054,000.00 | 1,674,469,000.00 | 74,400,000.00 | 202,952,000.00 | 15,654,000.00 | 187,298,000.00 | 0.00 | 29,088,000.00 | 761,157,000.00 | 0.00 | 0.00 | 761,157,000.00 | 15,510,255,000.00 | 7,953,782,000.00 | 19,249,000.00 | 0.00 | 88,976,000.00 | 88,976,000.00 | 0.00 | 0.00 | 0.00 | 5,404,000.00 | 0.00 | 7,775,962,000.00 | 0.00 | 7,775,962,000.00 | 1,877,252,000.00 | 5,898,710,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7,556,473,000.00 | 171,827,000.00 | 0.00 | 0.00 | 0.00 | 2,198,571,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2,670,436,000.00 | 0.00 | 0.00 | 2,515,639,000.00 | 2,454,859,000.00 | 60,780,000.00 | 0.00 | 0.00 |
| 2023-03-31T00:00:00 | quarterly | 0.00 | 104,616,204.00 | 104,616,204.00 | 277,364,000.00 | 315,463,000.00 | 12,898,048,000.00 | 13,212,381,000.00 | 5,358,558,000.00 | 12,898,048,000.00 | 3,107,000.00 | 12,900,025,000.00 | 12,962,381,000.00 | 12,900,025,000.00 | 12,900,025,000.00 | 0.00 | 11,683,520,000.00 | 819,710,000.00 | 104,616,000.00 | 104,616,000.00 | 2,239,793,000.00 | 321,350,000.00 | 22,966,000.00 | 234,390,000.00 | 63,994,000.00 | 1,638,000.00 | 62,356,000.00 | 0.00 | 1,918,443,000.00 | 0.00 | 251,469,000.00 | 1,469,000.00 | 250,000,000.00 | 274,760,000.00 | 274,757,000.00 | 1,362,539,000.00 | 334,552,000.00 | 89,987,000.00 | 938,000,000.00 | 15,139,818,000.00 | 7,862,817,000.00 | 0.00 | 169,133,000.00 | 1,246,000.00 | 0.00 | 1,246,000.00 | 0.00 | 0.00 | 1,977,000.00 | 1,977,000.00 | 7,654,796,000.00 | -1,873,062,000.00 | 9,527,858,000.00 | 1,726,971,000.00 | 493,799,000.00 | 4,294,524,000.00 | 2,465,453,000.00 | 547,111,000.00 | 0.00 | 7,277,001,000.00 | 7,116,000.00 | 2,500,000.00 | 93,680,000.00 | 211,954,000.00 | 2,123,147,000.00 | 148,019,000.00 | 1,131,982,000.00 | 843,146,000.00 | 383,549,000.00 | 0.00 | 2,737,576,000.00 | -8,730,000.00 | 2,746,306,000.00 | 1,811,159,000.00 | 1,776,167,000.00 | 34,992,000.00 | 0.00 | 34,992,000.00 |
| 2023-03-31T00:00:00 | annual | 0.00 | 104,616,204.00 | 104,616,204.00 | 277,364,000.00 | 315,463,000.00 | 12,898,048,000.00 | 13,212,381,000.00 | 5,358,558,000.00 | 12,898,048,000.00 | 3,107,000.00 | 12,900,025,000.00 | 12,962,381,000.00 | 12,900,025,000.00 | 12,900,025,000.00 | 0.00 | 11,683,520,000.00 | 819,710,000.00 | 104,616,000.00 | 104,616,000.00 | 2,239,793,000.00 | 321,350,000.00 | 22,966,000.00 | 234,390,000.00 | 63,994,000.00 | 1,638,000.00 | 62,356,000.00 | 0.00 | 1,918,443,000.00 | 0.00 | 251,469,000.00 | 1,469,000.00 | 250,000,000.00 | 274,760,000.00 | 274,757,000.00 | 1,362,539,000.00 | 334,552,000.00 | 89,987,000.00 | 938,000,000.00 | 15,139,818,000.00 | 7,862,817,000.00 | 0.00 | 169,133,000.00 | 1,246,000.00 | 0.00 | 1,246,000.00 | 0.00 | 0.00 | 1,977,000.00 | 1,977,000.00 | 7,654,796,000.00 | -1,873,062,000.00 | 9,527,858,000.00 | 1,726,971,000.00 | 493,799,000.00 | 4,294,524,000.00 | 2,465,453,000.00 | 547,111,000.00 | 0.00 | 7,277,001,000.00 | 7,116,000.00 | 2,500,000.00 | 93,680,000.00 | 211,954,000.00 | 2,123,147,000.00 | 148,019,000.00 | 1,131,982,000.00 | 843,146,000.00 | 383,549,000.00 | 0.00 | 2,737,576,000.00 | -8,730,000.00 | 2,746,306,000.00 | 1,811,159,000.00 | 1,776,167,000.00 | 34,992,000.00 | 0.00 | 34,992,000.00 |
| 2022-03-31T00:00:00 | annual | 0.00 | 104,616,204.00 | 104,616,204.00 | 599,190,000.00 | 624,930,000.00 | 10,996,440,000.00 | 11,638,090,000.00 | 4,774,980,000.00 | 10,996,440,000.00 | 19,070,000.00 | 11,032,230,000.00 | 11,344,710,000.00 | 11,032,230,000.00 | 11,032,230,000.00 | 0.00 | 9,815,720,000.00 | 829,220,000.00 | 95,110,000.00 | 95,110,000.00 | 2,095,720,000.00 | 544,040,000.00 | 18,740,000.00 | 209,710,000.00 | 315,590,000.00 | 3,110,000.00 | 312,480,000.00 | 0.00 | 1,551,680,000.00 | 0.00 | 309,340,000.00 | 15,960,000.00 | 293,380,000.00 | 17,480,000.00 | 17,480,000.00 | 1,068,020,000.00 | 236,960,000.00 | 0.00 | 831,060,000.00 | 13,127,950,000.00 | 6,801,290,000.00 | 0.00 | 284,430,000.00 | 2,560,000.00 | 0.00 | 2,560,000.00 | 0.00 | 0.00 | 35,790,000.00 | 35,790,000.00 | 6,435,550,000.00 | -1,378,490,000.00 | 7,814,040,000.00 | 741,560,000.00 | 432,180,000.00 | 3,853,170,000.00 | 2,240,020,000.00 | 547,110,000.00 | 0.00 | 6,326,660,000.00 | 0.00 | 4,980,000.00 | 10,150,000.00 | 151,980,000.00 | 1,951,170,000.00 | 221,880,000.00 | 901,800,000.00 | 827,490,000.00 | 268,890,000.00 | 0.00 | 2,321,740,000.00 | -7,810,000.00 | 2,329,550,000.00 | 1,617,750,000.00 | 1,611,080,000.00 | 6,670,000.00 | 0.00 | 6,670,000.00 |
| 2021-03-31T00:00:00 | annual | 0.00 | 104,616,204.00 | 104,616,204.00 | 812,050,000.00 | 892,830,000.00 | 9,929,550,000.00 | 10,857,220,000.00 | 5,014,080,000.00 | 9,929,550,000.00 | 29,340,000.00 | 9,993,730,000.00 | 10,556,230,000.00 | 9,993,730,000.00 | 9,993,730,000.00 | 0.00 | 8,777,220,000.00 | 829,220,000.00 | 95,110,000.00 | 95,110,000.00 | 1,831,730,000.00 | 774,340,000.00 | 20,980,000.00 | 174,530,000.00 | 578,830,000.00 | 16,330,000.00 | 562,500,000.00 | 0.00 | 1,057,390,000.00 | 0.00 | 314,000,000.00 | 13,010,000.00 | 300,990,000.00 | 6,600,000.00 | 6,600,000.00 | 707,380,000.00 | 243,410,000.00 | 0.00 | 463,970,000.00 | 11,825,460,000.00 | 5,753,990,000.00 | 0.00 | 72,190,000.00 | 0.00 | 0.00 | 0.00 | 3,660,000.00 | 3,660,000.00 | 64,180,000.00 | 64,180,000.00 | 5,577,460,000.00 | -924,090,000.00 | 6,501,550,000.00 | 179,460,000.00 | 411,270,000.00 | 3,361,490,000.00 | 2,002,340,000.00 | 546,990,000.00 | 0.00 | 6,071,470,000.00 | 0.00 | 20,000.00 | 6,760,000.00 | 383,930,000.00 | 1,536,080,000.00 | 200,690,000.00 | 683,200,000.00 | 652,190,000.00 | 357,410,000.00 | 0.00 | 1,775,170,000.00 | -11,270,000.00 | 1,786,440,000.00 | 2,012,100,000.00 | 1,960,660,000.00 | 51,440,000.00 | 50,000.00 | 51,390,000.00 |
| 2020-03-31T00:00:00 | annual | 0.00 | 0.00 | 0.00 | 456,200,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2,840,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -10,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 38,040,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
NSE: CONCORDBIO Cash Flow Data In (Cr)
| date | period_type | Free Cash Flow | Repayment Of Debt | Issuance Of Debt | Capital Expenditure | End Cash Position | Beginning Cash Position | Changes In Cash | Financing Cash Flow | Net Other Financing Charges | Interest Paid Cff | Cash Dividends Paid | Common Stock Dividend Paid | Net Issuance Payments Of Debt | Net Short Term Debt Issuance | Net Long Term Debt Issuance | Long Term Debt Payments | Long Term Debt Issuance | Investing Cash Flow | Interest Received Cfi | Net Investment Purchase And Sale | Sale Of Investment | Purchase Of Investment | Net PPE Purchase And Sale | Sale Of PPE | Purchase Of PPE | Operating Cash Flow | Taxes Refund Paid | Change In Working Capital | Change In Other Current Liabilities | Change In Other Current Assets | Change In Payable | Change In Inventory | Change In Receivables | Other Non Cash Items | Provisionand Write Offof Assets | Depreciation And Amortization | Amortization Cash Flow | Depreciation | Gain Loss On Investment Securities | Net Foreign Currency Exchange Gain Loss | Gain Loss On Sale Of PPE | Net Income From Continuing Operations |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31T00:00:00 | annual | 1,797,786,000.00 | -250,058,000.00 | 0.00 | -856,885,000.00 | 151,421,000.00 | 34,992,000.00 | 116,429,000.00 | -992,149,000.00 | 13,912,000.00 | -26,496,000.00 | -714,529,000.00 | -714,529,000.00 | -250,058,000.00 | 0.00 | -250,058,000.00 | -250,058,000.00 | 0.00 | -1,546,093,000.00 | 27,728,000.00 | -718,687,000.00 | 7,662,313,000.00 | -8,381,000,000.00 | -855,134,000.00 | 1,751,000.00 | -856,885,000.00 | 2,654,671,000.00 | -1,033,496,000.00 | -811,798,000.00 | 61,309,000.00 | 3,329,000.00 | -112,866,000.00 | 43,609,000.00 | -786,596,000.00 | -15,688,000.00 | 6,313,000.00 | 535,915,000.00 | 3,388,000.00 | 532,527,000.00 | -140,647,000.00 | 22,254,000.00 | -119,000.00 | 4,125,650,000.00 |
| 2023-03-31T00:00:00 | annual | 1,009,170,000.00 | -250,000,000.00 | 0.00 | -1,450,848,000.00 | 34,992,000.00 | 6,669,000.00 | 28,323,000.00 | -852,194,000.00 | 32,356,000.00 | -39,582,000.00 | -535,635,000.00 | -535,635,000.00 | -293,372,000.00 | -43,372,000.00 | -250,000,000.00 | -250,000,000.00 | 0.00 | -1,579,501,000.00 | 55,849,000.00 | -184,755,000.00 | 6,246,237,000.00 | -6,430,992,000.00 | -1,450,595,000.00 | 253,000.00 | -1,450,848,000.00 | 2,460,018,000.00 | -702,766,000.00 | -522,855,000.00 | -92,053,000.00 | -191,310,000.00 | 98,806,000.00 | -172,273,000.00 | -430,971,000.00 | -21,947,000.00 | -16,585,000.00 | 540,324,000.00 | 33,794,000.00 | 506,530,000.00 | -37,169,000.00 | 19,535,000.00 | 940,000.00 | 3,220,134,000.00 |
| 2022-03-31T00:00:00 | annual | 519,700,000.00 | -250,020,000.00 | 0.00 | -1,555,050,000.00 | 6,670,000.00 | 51,440,000.00 | -44,770,000.00 | -1,001,640,000.00 | 30,890,000.00 | -53,150,000.00 | -705,210,000.00 | 0.00 | -257,630,000.00 | -7,610,000.00 | -250,020,000.00 | -250,020,000.00 | 0.00 | -1,117,880,000.00 | 41,390,000.00 | 395,220,000.00 | 5,614,360,000.00 | -5,219,140,000.00 | -1,554,490,000.00 | 560,000.00 | -1,555,050,000.00 | 2,074,750,000.00 | -607,850,000.00 | -220,530,000.00 | 114,060,000.00 | 241,700,000.00 | 365,320,000.00 | -415,090,000.00 | -527,690,000.00 | -22,400,000.00 | 19,240,000.00 | 500,500,000.00 | 33,950,000.00 | 466,550,000.00 | -52,300,000.00 | -18,350,000.00 | 340,000.00 | 2,375,180,000.00 |
| 2021-03-31T00:00:00 | annual | -373,590,000.00 | -187,500,000.00 | 519,720,000.00 | -2,041,760,000.00 | 51,440,000.00 | 24,080,000.00 | 27,360,000.00 | 311,240,000.00 | 0.00 | 0.00 | -57,060,000.00 | 0.00 | 383,210,000.00 | 50,990,000.00 | 332,220,000.00 | -187,500,000.00 | 519,720,000.00 | -1,952,050,000.00 | 1,070,000.00 | 88,640,000.00 | 6,823,740,000.00 | -6,735,100,000.00 | -2,041,760,000.00 | 0.00 | -2,041,760,000.00 | 1,668,170,000.00 | -751,770,000.00 | -887,630,000.00 | -151,240,000.00 | -160,780,000.00 | -225,100,000.00 | -423,770,000.00 | 65,010,000.00 | -10,490,000.00 | -22,130,000.00 | 275,230,000.00 | 32,580,000.00 | 242,650,000.00 | -69,860,000.00 | -1,750,000.00 | 0.00 | 3,127,200,000.00 |
| 2020-03-31T00:00:00 | annual | 0.00 | 0.00 | 480,280,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 480,280,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
NSE: CONCORDBIO Income Statement Data In (Cr)
| date | period_type | Tax Effect Of Unusual Items | Tax Rate For Calcs | Normalized EBITDA | Total Unusual Items | Total Unusual Items Excluding Goodwill | Net Income From Continuing Operation Net Minority Interest | Reconciled Depreciation | Reconciled Cost Of Revenue | EBITDA | EBIT | Net Interest Income | Interest Expense | Interest Income | Normalized Income | Net Income From Continuing And Discontinued Operation | Total Expenses | Rent Expense Supplemental | Diluted Average Shares | Basic Average Shares | Diluted EPS | Basic EPS | Diluted NI Availto Com Stockholders | Net Income Common Stockholders | Otherunder Preferred Stock Dividend | Net Income | Net Income Including Noncontrolling Interests | Net Income Continuous Operations | Tax Provision | Pretax Income | Other Non Operating Income Expenses | Special Income Charges | Other Special Charges | Write Off | Net Non Operating Interest Income Expense | Total Other Finance Cost | Interest Expense Non Operating | Interest Income Non Operating | Operating Income | Operating Expense | Other Operating Expenses | Depreciation And Amortization In Income Statement | Amortization | Depreciation Income Statement | Selling General And Administration | Selling And Marketing Expense | General And Administrative Expense | Rent And Landing Fees | Gross Profit | Cost Of Revenue | Total Revenue | Operating Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31T00:00:00 | annual | 3.63 | 0.00 | 454.49 | 14.22 | 14.22 | 308.10 | 53.59 | 241.61 | 468.71 | 415.12 | -0.14 | 2.55 | 3.04 | 297.52 | 308.10 | 611.77 | 8.56 | 10.46 | 10.46 | 0.00 | 0.00 | 308.10 | 308.10 | 0.00 | 308.10 | 308.10 | 308.10 | 104.46 | 412.57 | 2.36 | 0.15 | -0.15 | 0.00 | -0.14 | 0.63 | 2.55 | 3.04 | 386.28 | 370.16 | 166.95 | 53.59 | 0.34 | 53.25 | 44.24 | 33.11 | 11.13 | 8.56 | 756.45 | 241.61 | 998.06 | 998.06 |
| 2023-03-31T00:00:00 | annual | 1.09 | 0.00 | 376.31 | 4.24 | 4.24 | 240.09 | 54.03 | 197.07 | 380.56 | 326.52 | -0.74 | 4.51 | 4.44 | 236.93 | 240.09 | 525.89 | 5.90 | 10.46 | 10.46 | 0.00 | 0.00 | 240.09 | 240.09 | 0.00 | 240.09 | 240.09 | 240.09 | 81.93 | 322.01 | 1.59 | 0.53 | -0.53 | 0.00 | -0.74 | 0.67 | 4.51 | 4.44 | 304.75 | 328.82 | 155.10 | 54.03 | 3.38 | 50.65 | 34.20 | 23.70 | 10.50 | 5.90 | 633.57 | 197.07 | 830.63 | 830.63 |
| 2022-03-31T00:00:00 | annual | -0.25 | 0.00 | 294.01 | -0.96 | -0.96 | 174.93 | 50.05 | 177.92 | 293.05 | 243.00 | -1.35 | 5.48 | 4.79 | 175.63 | 174.93 | 472.31 | 0.00 | 10.46 | 10.46 | 0.00 | 0.00 | 174.93 | 174.93 | 0.00 | 174.93 | 174.93 | 174.93 | 62.59 | 237.52 | 0.97 | -6.19 | -0.27 | 6.45 | -1.35 | 0.65 | 5.48 | 4.79 | 236.13 | 294.39 | 126.49 | 50.05 | 3.40 | 46.66 | 32.02 | 21.44 | 10.58 | 0.00 | 530.52 | 177.92 | 708.44 | 708.44 |
| 2021-03-31T00:00:00 | annual | 1.62 | 0.00 | 334.41 | 6.50 | 6.50 | 234.89 | 27.52 | 120.33 | 340.91 | 313.39 | 0.74 | 0.67 | 1.79 | 230.00 | 234.89 | 300.80 | 0.00 | 10.46 | 10.46 | 0.00 | 0.00 | 234.89 | 234.89 | 0.00 | 234.89 | 234.89 | 234.89 | 77.83 | 312.72 | 1.13 | -0.49 | 0.00 | 0.49 | 0.74 | 0.38 | 0.67 | 1.79 | 303.25 | 180.48 | 76.01 | 27.52 | 3.26 | 24.27 | 20.46 | 13.36 | 7.09 | 0.00 | 483.73 | 120.33 | 604.05 | 604.05 |
| 2020-03-31T00:00:00 | annual | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.17 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
FII & DII Data (In Cr)
| Date | FII Gross Purchase | FII Gross Sales | FII Net Purchase / Sales | DII Gross Purchase | DII Gross Sales | DII Net Purchase / Sales |
|---|---|---|---|---|---|---|
| 2025-02-03 | 12,505.92 | 16,464.29 | -3,958.37 | 19,319.48 | 16,611.25 | 2,708.23 |
| 2025-01-30 | 10,513.63 | 15,096.58 | -4,582.95 | 13,934.35 | 11,768.46 | 2,165.89 |
| 2025-01-29 | 7,644.40 | 10,230.83 | -2,586.43 | 12,871.38 | 11,078.67 | 1,792.71 |
| 2025-01-27 | 9,488.57 | 14,504.03 | -5,015.46 | 16,503.43 | 9,861.28 | 6,642.15 |
| 2025-01-24 | 11,230.47 | 13,988.96 | -2,758.49 | 12,835.41 | 10,433.10 | 2,402.31 |
| 2025-01-23 | 13,316.55 | 18,779.07 | -5,462.52 | 14,412.73 | 10,700.18 | 3,712.55 |
| 2025-01-22 | 12,936.64 | 16,962.89 | -4,026.25 | 15,437.18 | 11,796.96 | 3,640.22 |
Piotroski F-Score
5/9
0
1
2
3
4
5
6
7
8
9
Key Metrics
EPS
31.3
P/E
67.01278
P/B
13.799978
Dividend Yield
0.41%
Market Cap
21,943.21 Cr.
Face Value
151.993
Book Value
151.993
ROE
30.2%
EBITDA Growth
465.23 Cr.
Debt/Equity
0.215
Short Term
Subscribe to unlock this feature
Medium Term
Subscribe to unlock this feature
Long Term
Subscribe to unlock this feature
Yearly Stock Performance Heatmap
Latest Updates
Ashoka Buildcon Arm Signs Rs 1,391 Crore Pact With NHAI
Ashoka Buildcon Ltd. announced on Monday, via an exchange filing, that its wholly owned subsidiary, Ashoka Bowaichandi Guskara Road Pvt Ltd., has exec...
Budget 2025: Rahul Bajoria On Addressing Income Growth And Consumption Trends
"However, discretionary, high-value consumption is taking a step back due to income growth settling at high single digits." Over the past fe...
FPIs Stay Net Sellers, Sell Stocks Worth Rs 2,575 Crore
Foreign portfolio investors stayed net sellers for the second straight session on Monday and sold stocks worth approximately Rs 2,575.1 crore, accordi...
Budget 2025: AMFI Seeks Tax Policy Reforms To Drive Mutual Fund Investments In 15-Point Proposal
The Association of Mutual Funds of India on Monday released a 15-point proposal for Union Budget 2025-26 requesting changes in tax policies that are i...
Apple iPhone SE 4: Price To Features, 11 Things You Need To Know
iPhone 16e (Not iPhone SE 4): If recent reports are to be believed, Apple may discontinue the SE label and rename iPhone SE 4 as iPhone 16e. Most Affo...
Rupee Closed Weaker Against The US Dollar
The rupee weakened by five paise to close at 85.83 against the US dollar. The Indian rupee had declined to a fresh low against the US dollar during th...
Table Space Founder Amit Banerji Dies Of Heart Attack At Age Of 45
Amit Banerji, the founder, chairman and chief executive officer of managed workspace provider Table Space, died after suffering from a heart attack, r...
War Fatigue, Economic Breakdown Or Pro-West? Why Syria's Al-Sharaa Is Seen Soft On Israel
The strategic positions have been used by Israeli forces to carry out hundreds of strikes to destroy Syria's military infrastructure. In 2011, be...
Popular Questions
What is the Market Cap of concordbio?
The market capitalization of Concord Biotech Limited is ₹21,943 Cr as of 05 Feb 2025.
What are the PE and PB ratios of Concord Biotech Limited?
The PE and PB ratios of Concord Biotech Limited are Not Available and 13.799978 respectively as of 05 Feb 2025.
What is the 52 Week High of Concord Biotech Limited?
The 52-week high of Concord Biotech Limited is ₹2664 as of 05 Feb 2025.
What is the 52 Week Low of Concord Biotech Limited?
The 52-week low of Concord Biotech Limited is ₹1327.05 as of 05 Feb 2025.
What are the earnings per share (EPS) for Concord Biotech Limited?
The Earnings Per Share (EPS) of Concord Biotech Limited is ₹31.3 as per the most recent quarterly results available on Fincept.
What is the ROE (Return on Equity) of Concord Biotech Limited?
The Return on Equity (ROE) of Concord Biotech Limited is 30.2% as per the most recent financial year data. Explore more on Fincept.